Truist initiated coverage of Xencor (XNCR) with a Buy rating and $29 price target Lead program, TL1A, has early data suggesting potential for sustained target engagement and the company’s broader immunology and inflammation pipeline leverages Xencor’s expertise in T-cell engagers, supported by its “deep oncology roots” and prior validation through xaluritamig, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor’s Promising Oncology and Autoimmune Advances Justify Buy Rating with $38 Price Target
- Xencor price target raised to $42 from $40 at Cantor Fitzgerald
- Xencor price target lowered to $18 from $20 at JPMorgan
- Xencor Reports Improved Q3 2025 Financial Results
- Xencor’s Promising Clinical Updates and Strong Efficacy Support Buy Rating